Connor, Clark & Lunn Investment Management Ltd. Aclaris Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 908,819 shares of ACRS stock, worth $2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
908,819
Previous 332,406
173.41%
Holding current value
$2 Million
Previous $375,000
500.8%
% of portfolio
0.01%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ACRS
# of Institutions
87Shares Held
60.6MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$31.4 Million21.95% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$19.6 Million4.3% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD6.2MShares$13.6 Million0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$9.52 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$7.42 Million0.0% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $147M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...